Pages that link to "Q34108534"

The following pages link to Bile acids improve the antimicrobial effect of rifaximin (Q34108534):

Displaying 38 items.

• Use of rifaximin in gastrointestinal and liver diseases (Q26740201) (← links)
• A role for the gut microbiota in IBS. (Q34416297) (← links)
• A single-component multidrug transporter of the major facilitator superfamily is part of a network that protects Escherichia coli from bile salt stress (Q34531336) (← links)
• Modulation of the fecal bile acid profile by gut microbiota in cirrhosis (Q34554908) (← links)
• Rifaximin for the treatment of acute infectious diarrhea (Q35090413) (← links)
• Review article: the antimicrobial effects of rifaximin on the gut microbiota (Q35855732) (← links)
• Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea (Q35855740) (← links)
• Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. (Q36009729) (← links)
• Rifaximin therapy of irritable bowel syndrome (Q37704526) (← links)
• Biologic properties and clinical uses of rifaximin (Q37827877) (← links)
• Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics (Q38122649) (← links)
• Challenges and opportunities in the management of Clostridium difficile infection (Q38228162) (← links)
• Rifaximin: beyond the traditional antibiotic activity (Q38237218) (← links)
• Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. (Q38340085) (← links)
• Nonantimicrobial drug targets for Clostridium difficile infections (Q38649348) (← links)
• Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome (Q38692607) (← links)
• Rifamycins, Alone and in Combination (Q38857578) (← links)
• Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study (Q38882409) (← links)
• Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation (Q39455595) (← links)
• In Vitro Antibacterial Activity of Unconjugated and Conjugated Bile Salts on Staphylococcus aureus (Q40063530) (← links)
• The influence of bile salts on the distribution of simvastatin in the octanol/buffer system. (Q40703785) (← links)
• Formulation and development of extended-release micro particulate drug delivery system of solubilized rifaximin (Q41124468) (← links)
• Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study (Q41688563) (← links)
• Rifaximin, Microbiota Biology, and Hepatic Encephalopathy (Q42324567) (← links)
• Current concepts in the pathophysiology and management of hepatic encephalopathy (Q42781012) (← links)
• Rifaximin for the treatment of hepatic encephalopathy. (Q42792218) (← links)
• Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps (Q42952867) (← links)
• Rifaximin fails to prevent campylobacteriosis in the human challenge model: a randomized, double-blind, placebo-controlled trial (Q46260190) (← links)
• Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. (Q46319853) (← links)
• Gut Microbiota-Based Therapies for Irritable Bowel Syndrome (Q49985626) (← links)
• Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles (Q59341136) (← links)
• Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease (Q64276819) (← links)
• Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review (Q89666569) (← links)
• Microbial metabolite deoxycholic acid shapes microbiota against Campylobacter jejuni chicken colonization (Q91650450) (← links)
• Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial (Q91735781) (← links)
• In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria (Q92450131) (← links)
• Microbiome modulates intestinal homeostasis against inflammatory diseases (Q93247005) (← links)
• Spiropiperidyl rifabutins: expanded in vitro testing against ESKAPE pathogens and select bacterial biofilms (Q97530767) (← links)